ArticleProceedings of the National Academy of Sciences of the United States of America2008
Comparative lesion sequencing provides insights into tumor evolution.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 444 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
444 citing papers in PubMed, 1 synthesis or guideline pooled it, 826 citations in OpenAlex.
- Machine learning-based meta-analysis of colorectal cancer and inflammatory bowel disease.PloS one · 2023Pooled it
- Spatiotemporal lineage tracing reveals the dynamic spatial architecture of tumor growth and metastasis.Nature genetics · 2026Article
- Is cancer the result of uncontrolled cellular growth? a glance into the tumorigenic process.Cancer cell international · 2026Review
- A Novel Self-Competitive Fishing Primer qPCR Approach for Efficient POLE Mutation Detection in Endometrial Cancer Molecular Classification.Current issues in molecular biology · 2026Article
- Selective sweep probabilities in spatially expanding populations.Nature communications · 2026Article
- Multiple small intestinal metastatic tumours: from basics to advanced testing.Oxford medical case reports · 2026Article
- Fulminant development of a giant pelvic metastasis from microsatellite-stable early-onset sigmoid colon cancer with KRAS and TP53 co-mutations: a case report.Frontiers in medicine · 2026Article
- State of omics-based microbial diagnostics of CRC.Gut microbes · 2025Review
- Single-dose DSS-induced inflammation enhances colorectal tumorigenesis in APC and KRAS mutant mice.Scientific reports · 2025Article
- Differentiation grade is highly concordant between matched primary and metastatic colorectal cancer.Clinical & experimental metastasis · 2025Article
- Detection of Cancers Three Years prior to Diagnosis Using Plasma Cell-Free DNA.Cancer discovery · 2025Article
- Article
- Circulating tumor cells: Blood-based detection, molecular biology, and clinical applications.Cancer cell · 2025Review
- Nanopore-based enzyme-linked immunosorbent assay for cancer biomarker detection.Nature nanotechnology · 2025Article
- Evolutionary paths towards metastasis.Nature reviews. Cancer · 2025Review
- Pooled analysis of 3,741 stool metagenomes from 18 cohorts for cross-stage and strain-level reproducible microbial biomarkers of colorectal cancer.Nature medicine · 2025Article
- Precision Oncology Framework Using Circulating Tumor Cells.International journal of molecular sciences · 2025Review
- Comprehensive bibliometric analysis and perspectives on therapies targeting colon cancer stem cells over a 40-year period.Regenerative therapy · 2025Article
- Clinical application and effectiveness analysis of modified Asia-Pacific colorectal cancer screening score combined with fecal occult blood test for colorectal cancer screening in asymptomatic population.BMC gastroenterology · 2025Article
- Quantifying cell divisions along evolutionary lineages in cancer.Nature genetics · 2025Article
384 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 3 countries.
Funding
Abstract
We show that the times separating the birth of benign, invasive, and metastatic tumor cells can be determined by analysis of the mutations they have in common. When combined with prior clinical observations, these analyses suggest the following general conclusions about colorectal tumorigenesis: (i) It takes approximately 17 years for a large benign tumor to evolve into an advanced cancer but <2 years for cells within that cancer to acquire the ability to metastasize; (ii) it requires few, if any, selective events to transform a highly invasive cancer cell into one with the capacity to metastasize; (iii) the process of cell culture ex vivo does not introduce new clonal mutations into colorectal tumor cell populations; and (iv) the rates at which point mutations develop in advanced cancers are similar to those of normal cells. These results have important implications for understanding human tumor pathogenesis, particularly those associated with metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.